rosiglitazone has been researched along with Atrial Remodeling in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Korantzopoulos, P; Li, G; Li, J; Liu, T; Zhao, H | 1 |
| Amin, R; Kariharan, T; Nanayakkara, G; Quindry, J; Viswaprakash, N; Zhong, J | 1 |
2 other study(ies) available for rosiglitazone and Atrial Remodeling
| Article | Year |
|---|---|
Rosiglitazone attenuates atrial structural remodeling and atrial fibrillation promotion in alloxan-induced diabetic rabbits.
Topics: Alloxan; Animals; Atrial Fibrillation; Atrial Function, Left; Atrial Remodeling; Biomarkers; Cardiac Pacing, Artificial; Diabetes Mellitus, Experimental; Fibrosis; Heart Atria; Hypoglycemic Agents; Inflammation Mediators; Oxidative Stress; Rabbits; Rosiglitazone; Thiazolidinediones; Time Factors | 2014 |
PPARĪ³ activation improves the molecular and functional components of I(to) remodeling by angiotensin II.
Topics: Angiotensin II; Animals; Atrial Remodeling; Cardiotonic Agents; Cells, Cultured; Diabetic Cardiomyopathies; Down-Regulation; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Myocytes, Cardiac; Oxidative Stress; Potassium Channels, Voltage-Gated; PPAR gamma; Protein Transport; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Rosiglitazone; Thiazolidinediones; Ventricular Remodeling | 2013 |